Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep 1;29(9):2631-2633.
doi: 10.1016/j.ymthe.2021.08.013. Epub 2021 Aug 24.

Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy

Axel Schambach  1 , Michael Morgan  2 , Boris Fehse  3
Affiliations
Comment

Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy

Axel Schambach et al. Mol Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Figures

Figure 1
Figure 1
Mechanisms that potentially contributed to malignant transformation of CD19-CAR T cells generated using PB transposons
See this image and copyright information in PMC

Comment on

References

    1. Micklethwaite K.P., Gowrishankar K., Gloss B.S., Li Z., Street J.A., Moezzi L., Mach M.A., Sutrave G., Clancy L.E., Bishop D.C. Investigation of product derived lymphoma following infusion of piggyBac modified CD19 chimeric antigen receptor T-cells. Blood. 2021 doi: 10.1182/blood.2021010858. Published online May 11, 2021. - DOI - PMC - PubMed
    1. Bishop D.C., Clancy L.E., Simms R., Burgess J., Mathew G., Moezzi L., Street, J.A., Sutrave, G., Atkins, E., McGuire, H.M. Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells. Blood. 2021 doi: 10.1182/blood.2021010813. Published online May 19, 2021. - DOI - PubMed
    1. Fraietta J.A., Nobles C.L., Sammons M.A., Lundh S., Carty S.A., Reich T.J., Cogdill A.P., Morrissette J.J.D., DeNizio J.E., Reddy S. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558:307–312. - PMC - PubMed
    1. Shah N.N., Qin H., Yates B., Su L., Shalabi H., Raffeld M., Ahlman M.A., Stetler-Stevenson M., Yuan C., Guo S. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Adv. 2019;3:2317–2322. - PMC - PubMed
    1. Newrzela S., Al-Ghaili N., Heinrich T., Petkova M., Hartmann S., Rengstl B., Kumar A., Jäck H.M., Gerdes S., Roeder I. T-cell receptor diversity prevents T-cell lymphoma development. Leukemia. 2012;26:2499–2507. - PubMed

Publication types

Substances

LinkOut - more resources